Novel Use of Pyrrolopyridine Derivatives for Preventing or Treating Inflammatory Diseases - Patent application

JP2023553944A5Inactive Publication Date: 2024-11-01VORONOI INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023535390
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-09
Filing Date
2021-12-09
Publication Date
2024-11-01
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current anti-inflammatory drugs have significant side effects and long-term use can lead to gastrointestinal disorders and other serious health issues, necessitating the development of a safer, effective alternative for preventing and treating inflammatory diseases.

Method used

Pyrrolopyridine derivatives are used as pharmaceutical compounds to inhibit the expression of inflammation-related factors such as NO, IL-6, and TNF-α, offering a safer and more effective treatment option for inflammatory diseases.

Benefits of technology

Pyrrolopyridine derivatives demonstrate excellent inhibitory activity against various protein kinases and inflammation-related factors, providing a potential treatment for conditions like inflammatory bowel disease, psoriasis, and rheumatoid arthritis with improved safety and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022123311000001
    Figure 2022123311000001
  • Figure 2022123311000002
    Figure 2022123311000002
  • Figure 2022123311000003
    Figure 2022123311000003
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for preventing and / or treating inflammatory diseases, the composition comprising a pyrrolopyridine derivative compound as an active ingredient. The compound represented by Chemical Formula 1 according to the present invention, or its enantiomer or a pharmaceutically acceptable salt thereof, has excellent inhibitory activity against not only protein kinases but also inflammatory factors and inflammatory cytokines. Therefore, pharmaceutical compositions comprising the compound as an active ingredient may be useful for preventing, treating, and / or ameliorating inflammatory diseases, particularly, but not limited to, inflammatory bowel disease, rheumatoid arthritis, or lupus.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Technical field of inventions This invention relates to novel uses of pyrrolopyridine derivative compounds for the prevention and / or treatment of inflammatory diseases. [Background technology]

[0002] Background of the Invention Pyrrolopyridine derivatives are bicyclic compounds formed by the linkage of pyridine and pyrrole, and are used for a variety of pharmaceutical purposes. Therefore, various pyrrolopyridine derivatives have been synthesized. Patent documents disclosing pyrrolopyridine derivatives include Korean Published Patent Nos. 10-2018-0015142, 10-2017-0106452, and 10-2017-0058465.

[0003] In most of the aforementioned patent documents, it may be known that pyrrolopyridine derivatives are used as inhibitors of protein kinases. Therefore, we have begun to identify other physiological activities and pharmacological mechanisms of pyrrolopyridine derivatives.

[0004] Inflammation is a mechanism that repairs living tissue damaged by physical action, chemicals, or bacterial infection. When the aforementioned stimuli are applied, vasoactive substances, such as histamine, serotonin, and prostaglandins, are released, increasing vascular permeability and causing inflammation.

[0005] It has been reported that when macrophages are activated by lipopolysaccharide (LPS), the TLR-4 signaling pathway is initiated, which includes phosphorylation of mitogen-activated protein kinase (MAPK) and activation of the transcription factor NF-κB (nuclear factor-kappa B). This induces the production of inflammation-related factors, such as NO, IL-6, IL-1β, TNF-α, iNOS, and COX-2 (Chae HS, et al. Biol Pharm Bull. 2009;32(4):553-557).

[0006] In recent years, active research has been conducted on methods for reducing the generation of inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs) containing bradykinin antagonists and TNF-α inhibitors having anti-inflammatory, analgesic, and antipyretic effects are commonly used as anti-inflammatory drugs. However, long-term use of non-steroidal anti-inflammatory drugs may cause gastrointestinal disorders, and serious side effects, such as secondary anemia, asthma, suppression of labor induction, harmful effects on the kidneys, liver damage, and allergies, have been reported. Therefore, there is a need to develop an anti-inflammatory agent that minimizes the commonly observed side effects of currently known anti-inflammatory agents, does not have an adverse effect on the human body, especially for maintenance use, and can be administered over a long period of time. Therefore, the present inventors discovered that pyrrolopyridine derivatives inhibit the expression of inflammatory cytokines, such as inflammatory-related factors including NO, IL-6, IL-1β, TNF-α, etc., and identified the possibility of using pyrrolopyridine derivatives as pharmaceuticals for preventing and / or treating inflammatory diseases by confirming their stability and safety in vivo.

Prior Art Documents

Patent Documents

[0007]

Patent Document 1

Patent Document 2

Patent Document 3

Non-Patent Documents

[0008]

Non-Patent Document 1

Summary of the Invention

[0009] Summary of the Invention The object of the present invention is to provide a pharmaceutical composition for preventing and / or treating inflammatory diseases, comprising a pyrrolopyridine derivative compound as an active ingredient.

[0010] Another object of the present invention is to provide a method for preventing and / or treating inflammatory diseases by targeting and administering an effective dose of a pyrrolopyridine derivative compound.

[0011] A further object of the present invention is to provide pyrrolopyridine derivative compositions for the prevention and / or treatment of inflammatory diseases, as well as for use in pharmaceutical compositions containing the same as an active ingredient.

[0012] In one embodiment, the present invention relates to a method for preventing and / or treating an inflammatory disease in a patient in need thereof, wherein the patient is given chemical formula 1: [ka] A method comprising administering a compound represented by, or its isomer, a pharmaceutically acceptable salt, or a pharmaceutical composition (wherein, R 1 These are C1-C3 alkoxy compounds. R 2 and R 3 Each of these is independently a hydrogen atom, a linear or branched C1-C atom, and a C1-C atom. 10 Alkyl, or C3-C6 cycloalkyl, R 4 It provides (which is a haloalkyl).

[0013] In one embodiment, the present invention provides a method for preventing and / or treating an inflammatory disease, comprising the step of administering an effective dose of a pharmaceutical composition comprising a compound represented by chemical formula 1, or an isomer thereof, or a pharmaceutically acceptable salt thereof.

[0014] The present invention provides the use of a compound represented by chemical formula 1, its isomers, pharmaceutically acceptable salts, or a pharmaceutical composition containing them as an active ingredient for the prevention and / or treatment of inflammatory diseases.

[0015] The compound represented by Chemical Formula 1 according to the present invention, or its isomer or pharmaceutically acceptable salt, has excellent inhibitory activity against various protein kinases, including DYRK1A and CLK, and / or against inflammation-related factors, while simultaneously having excellent in-vivo stability. Pharmaceutical compositions containing it as an active ingredient may be useful in treating and / or preventing inflammatory diseases. In certain embodiments, the compound of Chemical Formula 1 can be used to prevent, treat, and / or improve inflammatory bowel disease, psoriasis, rheumatoid arthritis, and lupus. [Brief explanation of the drawing]

[0016] [Figure 1A] Figures 1a and 1b show the inhibitory activity of compound 1 on the expression of pro-inflammatory cytokines TNF-α and IL-6 (Figure 1a), and the inhibitory activity on the nuclear mobility of p50 and p65, which are involved in the NF-κB signaling pathway (Figure 1b), when LPS-stimulated THP-1 cells are treated with compound 1. [Figure 1B] Figures 1a and 1b show the inhibitory activity of compound 1 on the expression of pro-inflammatory cytokines TNF-α and IL-6 (Figure 1a), and the inhibitory activity on the nuclear mobility of p50 and p65, which are involved in the NF-κB signaling pathway (Figure 1b), when LPS-stimulated THP-1 cells are treated with compound 1.

[0017] [Figure 2] Figure 2 shows the results of the evaluation of regulatory activity for the differentiation of regulatory T cells and Th17 cells.

[0018] [Figure 3-1]Figure 3 shows the results of treating a collagen-induced arthritis mouse model with compound 1 to evaluate the therapeutic effect on arthritis, and shows the results of arthritis index evaluation (a), joint weight measurement (b), and histological analysis observed under a microscope after staining with H&E and T-blue (c) to (e). [Figure 3-2] Figure 3 shows the results of treating a collagen-induced arthritis mouse model with compound 1 to evaluate the therapeutic effect on arthritis, and shows the results of arthritis index evaluation (a), joint weight measurement (b), and histological analysis observed under a microscope after staining with H&E and T-blue (c) to (e).

[0019] [Figure 4] Figure 4 shows the results of evaluating the inhibitory activity of compound 1 on the secretion of inflammatory cytokines (TNF-α, IL-6, and IL-17A) when peripheral blood mononuclear cells in the blood of inflammatory bowel disease patients were treated at various concentrations.

[0020] [Figure 5] Figure 5 shows the results of optical microscopy observations of colon tissue from a mouse model of TNBS-induced inflammatory bowel disease treated with compound 1, as well as Enbrel and cyclosporine A as comparative compounds, after H / E staining.

[0021] [Figure 6] Figure 6 shows the degree of myeloperoxidase (MPO) expression, as well as the weight and histological analysis results of colon tissue after treatment of a 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis model with compound 1.

[0022] [Figure 7] Figure 7 shows the results of efficacy evaluation after treating a mouse model of DSS (dextran sulfate sodium)-induced inflammatory bowel disease, including the effect on suppressing weight loss and the evaluation of the disease activity index (DAI).

[0023] [Figure 8A] Figures 8a to 8c show the expression of inflammatory cytokines in colon tissue of DSS-induced inflammatory bowel disease mouse models treated with compound 1 and the comparative compounds cyclosporine A and tofacitinib (Figure 8a), light micrographs of colon tissue after H / E staining (Figure 8b), and the results of scoring of weight-to-length ratio and goblet cell depletion in colon tissue (Figure 8c). [Figure 8B] Figures 8a to 8c show the expression of inflammatory cytokines in colon tissue of DSS-induced inflammatory bowel disease mouse models treated with compound 1 and the comparative compounds cyclosporine A and tofacitinib (Figure 8a), light micrographs of colon tissue after H / E staining (Figure 8b), and the results of scoring of weight-to-length ratio and goblet cell depletion in colon tissue (Figure 8c). [Figure 8C] Figures 8a to 8c show the expression of inflammatory cytokines in colon tissue of DSS-induced inflammatory bowel disease mouse models treated with compound 1 and the comparative compounds cyclosporine A and tofacitinib (Figure 8a), light micrographs of colon tissue after H / E staining (Figure 8b), and the results of scoring of weight-to-length ratio and goblet cell depletion in colon tissue (Figure 8c).

[0024] [Figure 9] Figure 9 shows the results of scoring the skin condition of a house dust mite-induced atopic dermatitis model to analyze the therapeutic effect of treating the model with compound 1.

[0025] [Figure 10] Figure 10 shows the results of evaluating the inhibitory activity of compound 1 on IL-4, IL-6, MIP-1b, KC, and IL-33 expression in skin tissue, as well as IgE expression in serum, when compound 1 was administered at different concentrations to a house dust mite-induced atopic dermatitis model.

[0026] [Figure 11A]Figures 11a and 11b show the results of the topical anti-inflammatory activity of compound 1 in an imiquimod (IMQ)-induced psoriasis-like skin inflammation model. [Figure 11B] Figures 11a and 11b show the results of the topical anti-inflammatory activity of compound 1 in an imiquimod (IMQ)-induced psoriasis-like skin inflammation model.

[0027] [Figure 12A] Figures 12a and 12b show the results of the oral anti-inflammatory activity of compound 1 in an imiquimod (IMQ)-induced psoriasis-like skin inflammation model. [Figure 12B] Figures 12a and 12b show the results of the oral anti-inflammatory activity of compound 1 in an imiquimod (IMQ)-induced psoriasis-like skin inflammation model. [Modes for carrying out the invention]

[0028] Detailed description of a particular embodiment 1. General description of a specific embodiment of the invention: Examples of the present invention may be modified in various different forms, and the scope of the present invention is not limited to the examples described below. Furthermore, examples of the present invention are provided to more fully illustrate the present invention to those skilled in the art. Furthermore, throughout this specification, "comprising" an element means that, unless otherwise specified, it does not exclude other elements, but rather that it may further include other elements.

[0029] 2. Compounds and Definitions: The compounds of the present invention include those generally described herein and are further indicated by the classes, subclasses, and species disclosed herein. Where used herein, unless otherwise indicated, the following definitions should apply. For the purposes of this invention, chemical elements are those defined in the Periodic Table, CAS version, Handbook of Chemistry and Physics, 75 thIt is identified according to Ed. Further, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5 th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire content of which is hereby incorporated by reference into this specification.

[0030] As used herein, the term "administering" refers to using a method suitable for introducing the pharmaceutical composition of the present invention into a subject suspected of having an inflammatory disease, and administering may be carried out via various routes as long as the target tissue can be reached.

[0031] As used herein, the term "alkyl" may mean a straight-chain or branched acyclic saturated hydrocarbon consisting of carbon atoms. Representative -(C 1~8 alkyl) may include methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl; branched-chain saturated alkyl may include isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. C 1~8 alkyl may be either substituted or unsubstituted. For example, a C 1~8 alkyl group may be substituted with phenyl to form a benzyl group.

[0032] As used herein, the phrase “administered together” means, in this specification, any combination of two or more different therapeutic compounds in which a second administered compound is administered while the first administered therapeutic compound remains effective in the body (for example, both compounds are effective simultaneously in the patient, which may include an additive or synergistic effect of the two compounds).

[0033] As used herein, the term "cycloalkyl" may refer to a non-aromatic saturated or unsaturated carbon ring. Representative cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, cycloheptyl, 1,3-cycloheptadienyl, 1,3,5-cycloheptatrielinyl, cyclooctyl, and cyclooctadienyl. Cycloalkyl groups may be substituted or unsubstituted. In one embodiment, the cycloalkyl group is C 3~8 They may be cycloalkyl groups. C7 or more cycloalkyl groups may have two or more cyclic structures, and a particular example thereof may be a bicycloalkyl group, and more specifically, bicycloheptane may be used in the present invention.

[0034] At least one of the homogeneous or heterogeneous substituents mentioned above may be substituted at the same position or at different positions, and may be substituted sequentially. The term “sequentially” above refers to a substitution of one substituent in the chemical formula followed by a sequential substitution of another substituent. For example, if an alkyl group is substituted, then a cycloalkyl group is substituted on that alkyl group, and then a carbonyl group is sequentially substituted on that cycloalkyl group, the compound may be named carbonylcycloalkylalkyl to indicate that it has been sequentially substituted.

[0035] As used herein, the term "halogen" may be F, Cl, Br, or I.

[0036] As used herein, the term "haloalkyl" may refer to a linear or branched alkyl (hydrocarbon) having carbon atoms substituted with at least one halogen atom. Examples of haloalkyls, but not limited to these, include methyl, ethyl, propyl, isopropyl, isobutyl, and N-butyl, which are independently substituted with at least one halogen atom, e.g., F, Cl, Br, or I.

[0037] As used herein, the term “hydrate” refers to a compound of the present invention, or a salt thereof, containing a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. Hydrates of compounds represented by Formula 1 of the present invention may contain a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. Such hydrates may contain at least 1 equivalent, preferably 1 to 5 equivalents, of water. Such hydrates may be prepared by crystallizing a compound represented by Chemical Formula 1 of the present invention, its isomers, or pharmaceutically acceptable salts from water or a water-containing solvent.

[0038] As used herein, the term “isomer” refers to a compound or salt thereof of the present invention that has the same chemical or molecular formula but is structurally or sterically different. Such isomers include all structural isomers, e.g., tautomers, R or S isomers, stereoisomers, e.g., geometric isomers (trans, cis), and enantiomers. All such isomers and compounds are also included in the scope of the present invention. Unless otherwise specified, solid-line bonds (-) attached to a chiral carbon atom represent wedge-shaped bonds, where the absolute configuration of the stereocenter is represented. [ka] Or a dashed wedge-shaped connection [ka] It may include.

[0039] As used herein, the term “inflammatory disease” is a general term referring to any disease in which inflammation is the primary condition, and may include, in particular, but is not limited to, asthma, acute lung injury, GvHD (graft-versus-host disease), chronic obstructive pulmonary disease, allergies, systemic lupus erythematosus, scleroderma, inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), atopic dermatitis, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular degeneration, uveitis, conjunctivitis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic nephropathy, nephritis, Sjögren's syndrome, Crohn's disease, autoimmune pancreatitis, periodontal disease, alopecia areata, graft-versus-host disease, chronic pelvic peritonitis, endometriosis, rhinitis, tonsillitis, otitis media, pharyngitis, cystitis, and chronic prostatitis. Further inflammatory diseases or diseases having an inflammatory component are disclosed herein.

[0040] As used herein, the term “pharmaceutical effective dose” refers to a dose sufficient to treat a disease with a reasonable benefit / risk ratio applicable to the medical treatment, and the level of the effective dose may be determined according to factors including the type of subject, the severity of the disease, age, sex, type of disease, drug activity, drug sensitivity, duration of administration, route of administration, and excretion rate, treatment duration, and any drugs used in association with it, as well as other factors well known in the medical field. The compounds or compositions of the present invention may be administered as a single drug or in association with other drugs, for example by co-administration, or sequentially or concurrently with commercially available therapeutic agents. Furthermore, they may be administered as single doses or multiple doses. Taking all of the above factors into consideration, it is important to administer a dose that can achieve the maximum effect with the minimum amount without causing adverse effects; the dose may be readily determined by those skilled in the art. The dosage of the compounds or compositions of the present invention may be determined by a professional according to various factors, such as the patient’s condition, age, sex, and complications. The compounds or compositions of the present invention have excellent safety and may be used at the dosages determined above.

[0041] As used herein, the term “pharmaceutically acceptable salt” refers to a salt that is free from excessive toxicity, irritation, allergic reactions, etc., and that is commensurate with a reasonable benefit-to-risk ratio, and is suitable for use in contact with human and lower animal tissues within the bounds of sound medical judgment. pharmaceutically acceptable salts are well known in the art. For example, SMBerge et al., in J. Pharmaceutical Sciences, 1977, 66, 1-19, describe pharmaceutically acceptable salts in detail, which are incorporated herein by reference. Suitable pharmaceutically acceptable salts of the compounds of the present invention are derived from inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid adduct salts are salts of amino groups formed using inorganic acids, e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or organic acids, e.g., acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by other methods used in the art, e.g., ion exchange. Other pharmaceutically acceptable salts include adipine, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptone, glycerophosphate, gluconate, hemisulfonate, heptaneate, hexanoate, hydroiodide, and 2-hydroxyethanesulfonate. These include nitrates, lactobionates, lactates, laurates, lauryl sulfates, malates, maleates, malons, methanesulfonates, 2-naphthalenesulfonates, nicotinates, nitrates, oleates, oxalates, palmitates, pamoates, pectins, persulfates, 3-phenylpropionates, phosphates, pivalates, propions, stearates, succinates, sulfates, tartrates, thiocyanates, p-toluenesulfonates, undecanoates, and valersates.

[0042] Suitable base-derived salts include alkali metal salts, alkaline earth metal salts, ammonium salts, and N + (C 1~4 There are alkyl) tetrasalts. Typical alkali metal salts or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, where appropriate, non-toxic ammonium, quaternary ammonium, and amine cations formed using counterions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfons, and aryl sulfons. In some embodiments, compounds purified in the form of salts are provided for convenient and / or easy purification, for example, using an acidic or basic mobile phase during chromatography. The salt forms of the provided compounds formed during chromatographic purification (e.g., diammonium salts) are discussed herein and will be readily apparent to those skilled in the art.

[0043] As used herein, the term “solvate” refers to a compound of the present invention, or a salt thereof, containing a stoichiometric or nonstoichiometric amount of solvent bonded by non-covalent intermolecular forces. Therefore, preferred solvents include volatile or non-toxic solvents and / or solvents suitable for human administration.

[0044] As used herein, the terms “treatment” or “therapeutic” include suppressing, delaying, identifying, mitigating, weakening, limiting, reducing, inhibiting, avoiding, or curing the onset or progression / improvement of a disease, condition, disability, injury, or health problem, or the symptoms of such a condition and / or condition. The term “prevention” means avoiding or reducing the risk of suffering, experiencing, contracting, or having a disease, condition, disability, injury, or health problem, or the onset or progression of the symptoms of such a condition and / or condition. Treatment or prevention of a disease, condition, disability, injury, or health problem may be partial or complete.

[0045] 3. Description of exemplary embodiments: The present invention relates to a compound for preventing and / or treating inflammatory diseases, comprising chemical formula 1: [ka] The present invention provides a compound represented by, or its isomer, a pharmaceutically acceptable salt, or a pharmaceutical composition (wherein, R 1 These are C1-C3 alkoxy compounds. R 2 and R 3 Each of these is independently a hydrogen atom, a linear or branched C1-C atom, and a C1-C atom. 10 Alkyl, or C3-C6 cycloalkyl, R 4 (It is a haloalkyl.)

[0046] As defined and described herein, R 1 These are C1-C3 alkoxy compounds.

[0047] In some embodiments, R 1 is a C1-C3 alkoxy. In some embodiments, R 1 It is methoxy.

[0048] In some embodiments, R 1 This is observed in the compounds listed in Table 1 below.

[0049] As defined and described herein, R 2 and R 3 Each of these is independently a hydrogen atom, a linear or branched C1-C atom, and a C1-C atom. 10 They are alkyl or C3-C6 cycloalkyl groups.

[0050] In some embodiments, R 2 is hydrogen. In some embodiments, R 2 This is a linear C1-C 10 It is alkyl. In some embodiments, R 2 This is a branched C1~C 10It is alkyl. In some embodiments, R 2 is a C3-C6 cycloalkyl group. In some embodiments, R 2 These are linear or branched C1-C5 alkyl groups, or C3-C4 cycloalkyl groups.

[0051] In some embodiments, R 3 is hydrogen. In some embodiments, R 3 This is a linear C1-C 10 It is alkyl. In some embodiments, R 3 This is a branched C1~C 10 It is alkyl. In some embodiments, R 3 These are C3-C6 cycloalkyl groups.

[0052] In some embodiments, R 2 and R 3 This is observed in the compounds listed in Table 1 below.

[0053] As defined and described herein, R 4 It is a haloalkyl.

[0054] In some embodiments, R 4 is a haloalkyl. In some embodiments, R 4 It is trifluoromethyl.

[0055] In a particular embodiment, R 1 is methoxy; R 2 R is a linear or branched C1-C5 alkyl or C3-C4 cycloalkyl group; 3 is hydrogen; R 4 It is trifluoromethyl.

[0056] In a particular embodiment, the compound represented by chemical formula 1 is (4-((-4-ethylamino)-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine-6-yl)amino)-3-methoxyphenyl)(4-morpholinopiperidine-1-yl)methanone.

[0057] In some embodiments, the compound represented by chemical formula 1 is found in Table 1 below.

[0058] In some embodiments, pharmaceutically acceptable salts of the compound represented by chemical formula 1 may be interpreted as existing in any crystalline or amorphous form, or in any form selected from the group including hydrates, solvates, or cocrystals thereof.

[0059] In some embodiments, the compounds of the present invention, their pharmaceutically acceptable salts, or pharmaceutical compositions can act as inhibitors of protein kinases. Furthermore, the compounds referred to herein can act as inhibitors of inflammation-related factors (e.g., cytokines).

[0060] In some embodiments, the protein kinase may be one or more of ALK, ALK(C1156Y), ALK(L1196M), CLK1, CLK2, CLK3, CLK4, CSNK1D, DYRK1A, DYRK1B, DYRK2, GAK, JNK1, LRRK2(G2019S), LTK, MYLK, PAK2, PHKG1, PHKG2, STK33, unphosphorylated ABL1, CAMK2D, CAMKK2, CHEK2, CSNK1A1, CSNK1E, ERK5, HUNK, INSR, JAK1 (JH2 domain pseudokinase), JNK2, JNK3, LRRK2, MAPKAPK2, PLK4, and STK39.

[0061] Inflammation-related factors may refer to all factors known to be directly or indirectly associated with inflammatory responses. In certain examples of the present invention, inflammation-related factors may be pro-inflammatory cytokines whose activity is inhibited by the compounds of the present invention and thus exhibit a prophylactic and / or therapeutic effect against inflammation. These inflammation-related factors may be selected from, for example, one or more of NO, IFN-γ, IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17, IL-17A, IL-22, IL-23, IL-33, KC, MIP-1a, MIP-1b, GM-CSF, and TNF-α.

[0062] In some embodiments, the present invention provides a method for reducing pro-inflammatory cytokines in a patient in need thereof, comprising administering to the patient an effective dose of a compound represented by chemical formula 1, or its isomer, a pharmaceutically acceptable salt, or a pharmaceutical composition thereof. In some embodiments, the method for reducing pro-inflammatory cytokines reduces one or more of NO, IFN-γ, IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17, IL-17A, IL-22, IL-23, IL-33, KC, MIP-1a, MIP-1b, GM-CSF, and TNF-α. In certain embodiments, the method for reducing pro-inflammatory cytokines reduces one or more of IL-6, IL-17A, and TNF-α. In certain embodiments, the method for reducing pro-inflammatory cytokines reduces one or more of IL-4, IL-6, MIP-1b, KC, and IL-33. In some embodiments, the disclosed method reduces IL-4. In some embodiments, the disclosed method reduces IL-6. In some embodiments, the disclosed method reduces IL-17A. In some embodiments, the disclosed method reduces TNR-α. In some embodiments, the disclosed method reduces MIP-1b. In some embodiments, the disclosed method reduces KC. In some embodiments, the disclosed method reduces IL-33. In some embodiments, methods for reducing pro-inflammatory cytokines in a patient include preventing and / or treating inflammatory diseases, such as, but not limited to, inflammatory bowel disease or colitis.

[0063] In some embodiments, the present invention provides a method for reducing IgE in a patient in need, comprising administering to the patient an effective dose of a compound represented by chemical formula 1, or an isomer thereof, a pharmaceutically acceptable salt, or a pharmaceutical composition.

[0064] In some embodiments, the present invention relates to regulatory T cells (T) in patients who require it. regThe present invention provides a method for increasing the differentiation of regulatory T cells (T) in a patient, comprising administering to the patient an effective dose of a compound represented by chemical formula 1, or its isomer, a pharmaceutically acceptable salt, or a pharmaceutical composition thereof. In some embodiments, the method involves increasing the differentiation of regulatory T cells (T) in a patient. reg Methods to increase differentiation include preventing and / or treating inflammatory diseases, such as autoimmune diseases, but not limited to these.

[0065] In some embodiments, the present invention provides a method for reducing pro-inflammatory T cells (e.g., Th17) in a patient in need thereof, comprising administering to the patient an effective dose of a compound represented by chemical formula 1, or its isomers, pharmaceutically acceptable salts, or pharmaceutical compositions. In some embodiments, the method for reducing pro-inflammatory T cells (e.g., Th17) in a patient comprises preventing and / or treating inflammatory diseases, such as, but not limited to, autoimmune diseases.

[0066] In some embodiments, the present invention relates to regulatory T cells (T) in patients who require it. reg A method for increasing the differentiation of regulatory T cells (T17) and reducing pro-inflammatory T cells (e.g., Th17) is provided, comprising administering to a patient an effective dose of a compound represented by chemical formula 1, or its isomer, a pharmaceutically acceptable salt, or a pharmaceutical composition. In some embodiments, regulatory T cells (T17) in a patient are increased. reg Methods that increase the differentiation of pro-inflammatory T cells (e.g., Th17) and reduce pro-inflammatory T cells include preventing and / or treating inflammatory diseases, such as autoimmune diseases, but not limited to these.

[0067] In some embodiments, the inflammatory diseases that may be treated according to the methods of the present invention are, but are not limited to, Th17-mediated diseases. In some embodiments, the Th17-mediated diseases are selected from systemic lupus erythematosus, multiple sclerosis, and / or inflammatory bowel diseases, such as, but not limited to, Crohn's disease or ulcerative colitis.

[0068] In some embodiments, the present invention provides a method for preventing and / or treating an inflammatory disease for a patient in need thereof, comprising administering to the patient an effective dose of a compound represented by chemical formula 1, or an isomer thereof, a pharmaceutically acceptable salt, or a pharmaceutical composition thereof.

[0069] In some embodiments, the compounds of the present invention represented by chemical formula 1, or their isomers, pharmaceutically acceptable salts, or pharmaceutical compositions are useful in the prevention and / or treatment of inflammatory or obstructive airway diseases, for example, but not limited to, reducing tissue damage, airway inflammation, bronchial hypersensitivity, remodeling, or disease progression. In some embodiments, obstructive airway diseases include obstructive airway diseases having an inflammatory component. Inflammatory or obstructive airway diseases to which the present invention is applicable include, but are not limited to, asthma of any type or origin, including both endogenous (non-allergic) and exogenous (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchial asthma, exercise-induced asthma, occupational asthma, and asthma induced after bacterial infection. Treatment for asthma should also be understood to include treatment for subjects under 4 or 5 years of age, for example, those who exhibit wheezing symptoms, are an established category of patients of major medical concern, and are now often identified as early or early-stage asthma patients, or are diagnosed or diagnoseable as “wheezing infants.”

[0070] In some embodiments, the compounds of the present invention represented by chemical formula 1, or their isomers, pharmaceutically acceptable salts, or pharmaceutical compositions are useful in the prevention and / or treatment of heteroimmune diseases. Examples of such heteroimmune diseases, but not limited to, include graft-versus-host disease, transplantation, blood transfusion, anaphylaxis, allergies (e.g., allergies to plant pollen, latex, drugs, foods, insect toxins, animal hair, animal dander, house dust mites, cockroach calyx, or other sources), type I hypersensitivity, allergic conjunctivitis, allergic rhinitis, and atopic dermatitis.

[0071] With respect to the present invention, the prophylactic efficacy in the treatment of asthma will be demonstrated by a reduction in the frequency or severity of symptomatic attacks, including, but not limited to, acute asthmatic or bronchoconstrictor attacks, an improvement in lung function, and / or an improvement in airway responsiveness. Such efficacy may be further demonstrated by a reduction in the need for other symptomatic therapies, including, but not limited to, treatments intended to limit or interrupt symptomatic attacks when they occur, such as anti-inflammatory or bronchodilators. The prophylactic benefits in asthma may be particularly evident in subjects prone to exhibiting a “morning dip.” A morning dip is recognized as an asthmatic syndrome and is common in a significant percentage of asthma patients, characterized, for example, by an asthmatic attack occurring between approximately 4 and 6 a.m., i.e., usually a considerable time after any previously administered symptomatic asthma therapy.

[0072] In some embodiments, the compounds of the present invention represented by chemical formula 1, or their isomers, pharmaceutically acceptable salts, or pharmaceutical compositions are useful in the prevention and / or treatment of other inflammatory or obstructive airway diseases and conditions, including, but not limited to, acute lung injury (ALI), adult / acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, chronic bronchitis, or associated dyspnea, including airway or lung diseases (COPD, COAD, or COLD), emphysema, and other inflammatory or obstructive airway diseases and conditions, including exacerbations of increased airway reactivity resulting from other drug therapies, particularly other inhaled drug therapies. The present invention is also applicable to the prevention and / or treatment of bronchitis of any type or origin, including, but not limited to, acute, arachidin acidic, catarrhal, croup, chronic, or phthinoid bronchitis. Further inflammatory or obstructive airway diseases to which the present invention may apply include, but are not limited to, any type or origin of pneumoconiosis (an inflammatory, typically occupational lung disease, whether chronic or acute, frequently accompanied by airway obstruction, resulting from repeated inhalation of dust), including, for example, aluminum lung disease, anthracnose, asbestosis, lithiasis, ptosis, iron disease, silicosis, tobacco poisoning, and / or cotomatosis.

[0073] With respect to its anti-inflammatory activity, particularly in relation to the inhibition of eosinophil activation, the compound of the present invention represented by Chemical Formula 1, or its isomers, pharmaceutically acceptable salts, or pharmaceutical compositions are also useful in the prevention and / or treatment of eosinophil-related disorders, such as eosinophilia, particularly eosinophil-related disorders of the airways, including, but not limited to, hypereosinophilia affecting the airways and / or lungs (e.g., with pathological eosinophilic infiltration of lung tissue), as well as eosinophil-related disorders of the airways resulting from or associated with, for example, Loeffler syndrome, eosinophilic pneumonia, ectoparasitic infections (especially metazoans) (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma, and / or eosinophil-related disorders affecting the airways by drug reactions.

[0074] In some embodiments, the compounds of the present invention represented by chemical formula 1, or their isomers, pharmaceutically acceptable salts, or pharmaceutical compositions are useful in the prevention and / or treatment of inflammatory or allergic conditions of the skin; for example, but not limited to, psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforme, dermatitis herpetiformis, hidradenitis suppurativa, scleroderma, vitiligo, hypersensitivity vasculitis, urticaria, bullous pemphigoid, lupus erythematosus, systemic lupus erythematosus, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, acquired epidermolysis bullosa (EBA), acne vulgaris, and / or other inflammatory or allergic conditions of the skin.

[0075] In some embodiments, the compound of the present invention represented by chemical formula 1, or its isomers, pharmaceutically acceptable salts, or pharmaceutical compositions are not limited to, but include diseases or conditions having an inflammatory element; for example, graft-versus-host disease (GvHD), chronic obstructive airway disease, obstructive pulmonary disease, allergies, systemic lupus erythematosus, scleroderma, inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), atopic dermatitis, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular degeneration, uveitis, conjunctivitis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, Osteoporosis, diabetes, diabetic nephropathy, nephritis, Sjögren's syndrome, autoimmune pancreatitis, periodontal disease, alopecia areata, chronic pelvic peritonitis, endometriosis, rhinitis, tonsillitis, otitis media, pharyngitis, cystitis, chronic prostatitis, inflammatory diseases or conditions including eye diseases and conditions affecting the nose, such as eye allergies, keratoconjunctivitis sicca, vernal conjunctivitis, and allergic rhinitis, and / or, but not limited to, autoimmune blood disorders (e.g., hemolytic anemia, aplastic anemia, pure red cell adenomatosis, and idiopathic thrombocytopenia), polychondritis, Wegener's granulomatosis, dermatomyositis, Chronic active hepatitis, myasthenia gravis, Stevens-Johnson syndrome, idiopathic sprue, irritable bowel syndrome, celiac disease, periodontitis, pulmonary hyaline disease, renal disease, glomerular disease, alcoholic liver disease, multiple sclerosis, endocrine eye disorders, Becker / Duchenne muscular dystrophy, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis (anterior and posterior), interstitial pulmonary fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, cryopyrin-associated periodic syndromes, vasculitis, diverticulitis, interstitial cystitis, glomerulonephritis (e.g., idiopathic sprue), Nephrotic syndrome (with or without nephrotic syndrome, including Froets syndrome or minimal change nephropathy), chronic granulomatous disease, leptospirosis, nephrotic disease, glaucoma, retinal disease, aging, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscular atrophy, catabolic disorders, obesity, fetal growth restriction, hypercholesterolemia, heart disease, chronic heart failure, mesothelioma, anhidrotic ectodermal dysplasia, Behçet's disease, incontinentia pigmenti, Paget's disease, pancreatitis, hereditary periodic fever syndrome, asthma (allergic and non-allergic, mild, moderate, severe, bronchitis, and exercise-induced), acute lung injury, acute respiratory distress syndrome,Eosinophilia, hypersensitivity, rhinosinusitis, ocular allergies, silica-induced diseases, COPD (injury, airway inflammation, bronchial hypersensitivity, remodeling, or reduced disease progression), lung diseases, cystic fibrosis, acid-induced lung injury, pulmonary hypertension, polyneuropathy, cataracts, muscle inflammation with systemic sclerosis, inclusion body myositis, myasthenia gravis, thyroiditis, Addison's disease, lichen planus, diabetes mellitus (type 1 or type 2 diabetes), appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, colitis, dacryodenitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis It is useful in the prevention and / or treatment of inflammatory diseases involving autoimmune reactions or having autoimmune elements or etiologies, including epicondylitis, epididymitis, fasciitis, connective tissue inflammation, gastritis, gastroenteritis, Henoch-Schönlein purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, parotitis, pericarditis, peritonitis, pharyngitis, pleurisy, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, salpingitis, sinusitis, stomatitis, synovitis, tendinitis, tonsillitis, ulcerative colitis, vaginitis, vasculitis, and / or vulvitis.

[0076] In some embodiments, inflammatory diseases include, but are not limited to, asthma, acute lung injury, graft-versus-host disease (GvHD), chronic obstructive pulmonary disease, allergies, systemic lupus erythematosus, scleroderma, inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), atopic dermatitis, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular degeneration, uveitis, conjunctivitis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic nephropathy, nephritis, Sjögren's syndrome, Crohn's disease, autoimmune pancreatitis, periodontal disease, alopecia areata, graft-versus-host disease, chronic pelvic peritonitis, endometriosis, rhinitis, tonsillitis, otitis media, pharyngitis, cystitis, and chronic prostatitis. In certain embodiments, inflammatory diseases include, but are not limited to, inflammatory bowel disease, psoriasis, rheumatoid arthritis, and lupus.

[0077] In some embodiments, inflammatory diseases that may be prevented and / or treated according to the methods of the present invention are, but are not limited to, skin diseases. In some embodiments, inflammatory skin diseases are selected from, but are not limited to, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforme, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity vasculitis, urticaria, bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, acquired epidermolysis bullosa (EBA), and / or other inflammatory or allergic conditions of the skin.

[0078] In some embodiments, inflammatory diseases that may be prevented and / or treated according to the methods of the present invention are selected from, but are not limited to, acute and chronic gout, chronic gouty arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, systemic juvenile idiopathic arthritis (SJIA), cryopyrin-associated periodic syndromes (CAPS), and osteoarthritis.

[0079] In some embodiments, inflammatory diseases that may be prevented and / or treated according to the methods of the present invention are selected from, but are not limited to, Sjögren's syndrome, allergic disorders, osteoarthritis, eye conditions such as ocular allergies, conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, and / or diseases affecting the nose such as allergic rhinitis.

[0080] Furthermore, the present invention provides a method for improving, preventing, treating, and / or alleviating inflammation occurring on the skin and / or mucous membranes, comprising applying a compound represented by chemical formula 1, its isomers or pharmaceutically acceptable salts, or a pharmaceutical composition containing them, to a patient in need of improvement and / or relief of inflammation occurring on the skin and / or mucous membranes.

[0081] Furthermore, the present invention provides the use of a compound represented by chemical formula 1, its isomers, or pharmaceutically acceptable salts, or pharmaceutical compositions for use in the prevention and / or treatment of inflammatory diseases. In particular, the present invention provides the use of a compound represented by chemical formula 1, its isomers, pharmaceutically acceptable salts, or pharmaceutical compositions for producing a pharmacopoeia for use in the prevention and / or treatment of inflammatory diseases.

[0082] The pharmaceutical composition of the present invention, further comprising excipients, disintegrants, sweeteners, lubricants, flavoring agents, and the like, may be formulated using conventional methods into tablets, capsules, powders, granules, suspensions, emulsions, syrups, topicals, or other liquid, semi-liquid, or solid formulations. For example, since the pharmaceutical composition of the present invention may act systemically and / or locally and may be administered orally or parenterally, i.e., via various routes, for example, but not limited to, pulmonary administration, intranasal administration, sublingual administration, lingual administration, buccolingual administration, rectal administration, cutaneous administration, transdermal administration, or conjunctival administration, the pharmaceutical composition may be formulated into a form suitable for the route of administration. For example, suitable dosage forms for oral administration are, but are not limited to, formulations containing the compound of the present invention in crystalline and / or amorphous and / or soluble forms, which may be, for example, tablets (coated or uncoated tablets, e.g., using gastric acid-resistant, delayed-dissolving, or insoluble coatings), tablets or films / oblates that disintegrate rapidly in the mouth, film / freeze-dried preparations, capsules (e.g., hard or soft gelatin capsules), sugar-coated tablets, chewables (e.g., soft chewables), granules, pellets, powders, emulsions, suspensions, aerosols, and / or liquids. Parenteral administration may be achieved by avoiding the absorption step (e.g., via intravenous, intra-arterial, intracardiac, intrathecal, or intralumbar administration) or by involving absorption (e.g., via intramuscular, cutaneous, intradermal, subcutaneous, transdermal, or intraperitoneal routes). Suitable forms of administration for parenteral administration include, but are not limited to, liquid preparations, suspensions, emulsions, freeze-dried preparations, or sterile powders for injection.

[0083] In some embodiments, the present invention provides a method for preventing and / or treating an inflammatory disease for a patient in need thereof, comprising administering together an effective dose of a compound represented by chemical formula 1, or its isomer, a pharmaceutically acceptable salt, or a pharmaceutical composition, with at least one additional active ingredient.

[0084] In some embodiments, the pharmaceutical compositions of the present invention may contain at least one additional active ingredient in addition to the compounds of the present invention for more effective treatment and / or prevention of inflammatory diseases. Suitable active ingredients for combination include, but are not limited to, gamma globulin, immunomodulatory and immunosuppressive compounds (e.g., cyclosporine, methotrexate®), TNF antagonists (e.g., Humira®, etanercept, infliximab), IL-1 inhibitors (e.g., anakinra, canakinumab, lilonacept), phosphodiesterase inhibitors (e.g., apremilast), and JAK / STAT inhibitors (e.g., tofacitinib, baricitinib, GLPG0634). These include IRAK4 inhibitors, leflunomide, cyclophosphamide, rituximab, belimumab, tacrolimus, rapamycin, mycophenolate mofetil, interferon, corticosteroids (e.g., prednisone, prednisolone, methylprednisolone, hydrocortisone, betamethasone), cyclophosphamide, azathioprine, sulfasalazine, paracetamol, and / or nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen, naproxen, etodolac, celecoxib, colchicine).

[0085] Compounds represented by chemical formula 1, their isomers, pharmaceutically acceptable salts, or additional active agents that may be used in combination with the pharmaceutical composition may be small molecules or recombinant biological agents, for example, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS), such as aspirin, ibuprofen, naproxen, etodolac (Lodine®), and celecoxib, colchicine (Colcrys®), corticosteroids, such as prednisone, prednisolone, Methylprednisolone, hydrocortisone, probenecid, allopurinol, febuxostat (Uloric®), sulfasalazine (Azulfidine®), antimalarial drugs such as hydroxychloroquine (Plaquenil®) and chloroquine (Aralen®), methotrexate (Rheumatrex®), gold salts such as gold thioglucose (Solganal®), gold thiomalate (Myochrysine®), and auranofin (Ri Daura®, D-penicillamine (Depen® or Cuprimine®), azathioprine (Imuran®), cyclophosphamide (Cytoxan®), chlorambucil (Leukeran®), cyclosporine (Sandimmune®), leflunomide (Arava®), and "anti-TNF" agents, such as etanercept (Enbrel®), infliximab (Remicade®), golimumab (Simponi®), and registered trademarks. (Registered Trademark), certolizumab pegol (Cimzia®), and adalimumab (Humira®), "anti-IL-1" agents, e.g., anakinra (Kineret®) and lilonacept (Arcalyst®), canakinumab (Ilaris®), anti-Jak inhibitors, e.g., tofacitinib, antibodies, e.g., rituximab (Rituxan®), "anti-T cell" agents, e.g., abatacept (Orencia®), "anti-IL-6" agents, e.g., tocilizumab (Actemra®),Diclofenac, cortisone, hyaluronic acid (Synvisc® or Hyalgan®), monoclonal antibodies, e.g., tanezumab, anticoagulants, e.g., heparin (Calcinparine® or Liquaemin®), and warfarin (Coumadin®), antidiarrheal agents, e.g., diphenoxylate (Lomotil®) and loperamide (Imodium®), bile acid binders, e.g., cholestyramine, alosetron (Lotronex®) )), lubiprostone (Amitiza®), laxatives, e.g., magnesia milk, polyethylene glycol (MiraLax®), Dulcolax®, Correctol®, and Senokot®), anticholinergics or antispasmodics, e.g., dicyclomine (Bentyl®), Singulair®, beta-2 agonists, e.g., albuterol (Ventolin® HFA, Proventil® HFA), levalbuterol (Xopen ex(registered trademark)), metaproterenol (Alupent(registered trademark)), pyrbuterol acetate (Maxair(registered trademark)), terbutaline sulfate (Brethaire(registered trademark)), salmeterol xinafoate (Serevent(registered trademark)), and formoterol (Foradil(registered trademark)), anticholinergics, such as ipratropium bromide (Atrovent(registered trademark)) and tiotropium (Spiriva(registered trademark)), inhaled corticosteroids, such as beclomethasone dipropionate (Beclovent(registered trademark)) Qvar (registered trademark), and Vanceril (registered trademark), triamcinolone acetonide (Azmacort (registered trademark)), mometasone (Asthmanex (registered trademark)), budesonide (Pulmocort (registered trademark)), and flunisolide (Aerobid (registered trademark)), Afviar (registered trademark), Symbicort (registered trademark), Dulera (registered trademark), cromolyn sodium (Intal (registered trademark)), methylxanthine, for example, theophylline (Theo-Dur (registered trademark), Theolair (registered trademark)),Slo-Bid®, Uniphyl®, Theo-24®, and aminophyllines, IgE antibodies such as omalizumab (Xolair®), nucleoside reverse transcriptase inhibitors such as zidovudine (Retrovir®), abacavir (Ziagen®), abacavir / lamivudine (Epzicom®), abacavir / lamivudine / zidovudine (Trizivir®), didanosine (Videx®), emtricitabine (Emtr iva®, lamivudine (Epivir®), lamivudine / zidovudine (Combivir®), stabudine (Zerit®), and zalcitabine (Hivid®), non-nucleoside reverse transcriptase inhibitors, such as delavirudine (Rescriptor®), efavirenz (Sustiva®), nevirapine (Viramune®), and etravirine (Intelence®), nucleotides Reverse transcriptase inhibitors, e.g., tenofovir (Viread®), protease inhibitors, e.g., amprenavir (Agenerase®), atazanavir (Reyataz®), darunavir (Prezista®), fosamprenavir (Lexiva®), indinavir (Crixivan®), lopinavir and ritonavir (Kaletra®), nelfinavir (Viracept®), ritonavir (Norvir®), etc. Quinavir (Fortovase® or Invirase®), and tipranavir (Aptivus®), entry inhibitors such as enfuvirtide (Fuzeon®) and maraviroc (Selzentry®), integrase inhibitors such as raltegravir (Isentress®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), bortezomib (Velcade®),This includes and / or dexamethasone (Decadron®) in combination with lenalidomide (Revlimid®), or any combination thereof.

[0086] In another embodiment, the present invention provides a method for preventing and / or treating gout, comprising administering to a patient in need a compound of formula I and one or more additional active agents selected from nonsteroidal anti-inflammatory drugs (NSAIDS), such as aspirin, ibuprofen, naproxen, etodolac (Lodine®), and celecoxib, colchicine (Colcrys®), corticosteroids, such as prednisone, prednisolone, methylprednisolone, hydrocortisone, probenecid, allopurinol, and febuxostat (Uloric®).

[0087] In another embodiment, the present invention relates to a method for preventing and / or treating rheumatoid arthritis, comprising, to a patient in need, a compound of formula I and a nonsteroidal anti-inflammatory drug (NSAIDS), for example, but not limited to, aspirin, ibuprofen, naproxen, etodolac (Lodine®), and celecoxib; a corticosteroid, for example, prednisone, prednisolone, methylprednisolone, hydrocortisone, etc.; and sulfasalazine (Azulfidine®). Trademarks), antimalarial drugs, e.g., hydroxychloroquine (Plaquenil®) and chloroquine (Aralen®), methotrexate (Rheumatrex®), gold salts, e.g., gold thioglucose (Solganal®), gold thiomalate (Myochrysine®), and auranofin (Ridaura®), D-penicillamine (Depen® or Cuprimine®), azathio Purines (Imuran®), cyclophosphamide (Cytoxan®), chlorambucil (Leukeran®), cyclosporine (Sandimmune®), leflunomide (Arava®), and "anti-TNF" agents, such as etanercept (Enbrel®), infliximab (Remicade®), golimumab (Simponi®), certolizumab pegol (Cimzia®), and The present invention provides a method comprising administering one or more additional therapeutic agents selected from adalimumab (Humira®), "anti-IL-1" agents such as anakinra (Kineret®) and lilonacept (Arcalyst®), antibodies such as rituximab (Rituxan®), "anti-T cell" agents such as abatacept (Orencia®), and / or "anti-IL-6" agents such as tocilizumab (Actemra®).

[0088] In some embodiments, the present invention provides a method for preventing and / or treating osteoarthritis, comprising administering to a patient in need a compound of formula I and one or more additional therapeutic agents selected from acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS), such as aspirin, ibuprofen, naproxen, etodolac (Lodine®), and celecoxib, diclofenac, cortisone, hyaluronic acid (Synvisc® or Hyalgan®), and / or monoclonal antibodies, such as tanezumab.

[0089] In some embodiments, the present invention provides a method for preventing and / or treating lupus, comprising administering to a patient in need a compound of formula I and one or more additional therapeutic agents selected from acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS), e.g., aspirin, ibuprofen, naproxen, etodolac (Lodine®), and celecoxib, corticosteroids, e.g., prednisone, prednisolone, methylprednisolone, hydrocortisone, antimalarial drugs, e.g., hydroxychloroquine (Plaquenil®) and chloroquine (Aralen®), cyclophosphamide (Cytoxan®), methotrexate (Rheumatrex®), azathioprine (Imuran®), and / or anticoagulants, e.g., heparin (Calcinparine® or Liquaemin®), and warfarin (Coumadin®).

[0090] In some embodiments, the present invention provides a method for preventing and / or treating inflammatory bowel disease, comprising administering to a patient in need a compound of formula I, an antidiarrheal agent such as mesalamine (Asacol®), sulfasalazine (Azulfidine®), an antidiarrheal agent such as diphenoxylate (Lomotil®) and loperamide (Imodium®), a bile acid binder such as cholestyramine, alosetron (Lotronex®), lubiprostone (Amitiza®), a laxative such as magnesia milk, polyethylene glycol (MiraLax®), Dulcolax®, Correctol®, and Senokot®, and an anticholinergic or antispasmodic agent such as dicyclomine (Bentyl®), an anti-TNF therapy, a steroid, and / or an antibiotic such as Flagyl or ciprofloxacin.

[0091] In some embodiments, the present invention relates to a method for preventing and / or treating asthma, comprising, to a patient in need, a compound of formula I, and Singulair®, a beta-2 agonist, e.g., albuterol (Ventolin® HFA, Proventil® HFA), levalbuterol (Xopenex®), metaproterenol (Alupent®), pyrbuterol acetate (Maxair®), terbutaline sulfate (Brethaire®), salmeterol xinafoate (Serevent®), and formoterol (Foradil®), an anticholinergic agent, e.g., ipratropium bromide (Atrovent®) and tiotropium (Spiriva®), an inhaled corticosteroid, e.g., prednisone, prednisolone, beclomethasone dipropionate. The present invention provides a method comprising administering one or more additional therapeutic agents selected from zoon (Beclovent®, Qvar®, and Vanceril®), triamcinolone acetonide (Azmacort®), mometasone (Asthmanex®), budesonide (Pulmocort®), flunisolide (Aerobid®), Afviar®, Symbicort®, and Dulera®), cromolyn sodium (Intal®), methylxanthines, such as theophylline (Theo-Dur®, Theolair®, Slo-Bid®, Uniphyl®, Theo-24®), and aminophylline, and / or IgE antibodies, such as omalizumab (Xolair®).

[0092] In some embodiments, the present invention relates to a method for preventing and / or treating COPD, comprising, to a patient in need, a compound of formula I, a beta-2 agonist, e.g., albuterol (Ventolin® HFA, Proventil® HFA), levalbuterol (Xopenex®), metaproterenol (Alupent®), pyrbuterol acetate (Maxair®), terbutaline sulfate (Brethaire®), salmeterol xinafoate (Serevent®), and formoterol (Foradil®), an anticholinergic agent, e.g., ipratropium bromide (Atrovent®) and tiotropium (Spiriva®), a methylxanthine, e.g., theophylline (T The present invention provides a method comprising administering aminophylline, one or more additional therapeutic agents selected from, for example, prednisone, prednisolone, beclomethasone dipropionate (Beclovent, Qvar, and Vanceril), triamcinolone acetonide (Azmacort), mometasone (Asthmanex), budesonide (Pulmocort), flunisolide (Aerobid), Afviar, Symbicort, and / or Dulera.

[0093] Additional embodiments of the present invention are described below. These embodiments are illustrative and should not be construed as limiting the scope of the claimed invention.

[0094] Embodiment 1. A pharmaceutical composition for preventing and / or treating an inflammatory disease, comprising a compound represented by chemical formula 1, or an isomer thereof, or a pharmaceutically acceptable salt thereof, as an active substance. [ka] (In chemical formula 1 above, R 1 It is a C1-C3 alkoxy; R 2 and R 3 These are, independently, hydrogen, and a linear or branched chain of C1-C atoms. 10 Alkyl, or C3-C6 cycloalkyl; R 4 (It is a haloalkyl.)

[0095] Embodiment 2. The composition is R 1 is methoxy; R 2 However, it is a linear or branched C1-C5 alkyl or C3-C4 cycloalkyl; R 3 is hydrogen; R 4 A pharmaceutical composition for preventing and / or treating an inflammatory disease according to Embodiment 1, comprising, however, a compound which may be trifluoromethyl, or an isomer thereof, or a pharmaceutically acceptable salt thereof, as an active substance.

[0096] Embodiment 3. A pharmaceutical composition for preventing and / or treating an inflammatory disease of Embodiment 1, wherein the composition comprises a compound, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active substance, and the compound represented by chemical formula 1 may be (4-((-4-ethylamino)-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridine-6-yl)amino)-3-methoxyphenyl)(4-morpholinopiperidine-1-yl)methanone.

[0097] Embodiment 4. The composition contains a compound, its isomer, or a pharmaceutically acceptable salt as an active substance, and the inflammatory disease is asthma, acute lung injury, graft-versus-host disease (GvHD), chronic obstructive pulmonary disease, allergy, systemic lupus erythematosus, scleroderma, inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), atopic dermatitis, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular degeneration, uveitis, conjunctivitis, rheumatoid arthritis. A pharmaceutical composition for preventing and / or treating an inflammatory disease described in any one of Embodiments 1 to 3, which is at least one selected from the group consisting of ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes mellitus, diabetic nephropathy, nephritis, Sjögren's syndrome, Crohn's disease, autoimmune pancreatitis, periodontal disease, alopecia areata, graft-versus-host disease, chronic pelvic peritonitis, endometriosis, rhinitis, tonsillitis, otitis media, pharyngitis, cystitis, and chronic prostatitis.

[0098] Embodiment 5. A pharmaceutical composition for preventing and / or treating an inflammatory disease according to any one of Embodiments 1 to 3, wherein the composition comprises a compound, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active substance, and the inflammatory disease is at least one selected from the group including inflammatory bowel disease, rheumatoid arthritis, lupus, psoriasis, atopic dermatitis, graft-versus-host disease (GvHD), acute lung injury, alopecia areata, and osteoarthritis.

[0099] Embodiment 6. A pharmaceutical composition for preventing and / or treating an inflammatory disease according to any one of Embodiments 1 to 3, comprising as an active substance a compound that inhibits protein kinase activity, or an isomer thereof, or a pharmaceutically acceptable salt thereof.

[0100] Embodiment 7. A pharmaceutical composition for preventing and / or treating an inflammatory disease according to any one of Embodiments 1 to 3, comprising as an active substance a compound that inhibits inflammation-related factors, or an isomer thereof, or a pharmaceutically acceptable salt thereof.

[0101] The present invention will be described in more detail below through examples and experimental cases.

[0102] However, the following examples and experimental examples are intended solely to illustrate the present invention, and the scope of the present invention is not limited to the following examples and experimental examples. [Examples]

[0103] General synthesis methods The compounds of the present invention were prepared according to the method described in Korean Registered Patent Publication No. 10-1896568. The chemical structures, compound names, and H2 of compounds 1 to 5 are provided. 1 The NMR data is shown in Table 1 below. [Table 1-1] [Table 1-2]

[0104] (Example 1) Evaluation of the inhibitory activity of compounds according to the present invention against various kinases. The enzyme (kinase) selectivity and inhibitory activity of Compound 1, selected from the exemplary compounds of the present invention, were measured using DiscoverX and the scanMAX® Kinase analysis panel. The concentration of the drug used to treat the enzyme was 1 μM in DMSO; the percentage control (% control) was determined using the following method, and the results are shown in Table 2. [(Example compound - Positive control) / (Negative control - Positive control) × 100]

[0105] Here, a positive control refers to a compound exhibiting a 0% percentage control, and a negative control refers to a 100% percentage control containing DMSO. Furthermore, regarding the enzyme selectivity of the present invention, if the percentage control for each enzyme was <41% (i.e., less than 41%), the compound was judged to be active with respect to that enzyme. [Table 2]

[0106] As shown in Table 2 above, compound 1 exhibits inhibitory activity against various protein kinases.

[0107] (Example 2) Evaluation of the pro-inflammatory cytokine inhibitory activity of the compound according to the present invention. THP-1 cells were pre-treated with compound 1 for 1 hour, and then treated with the inflammatory substance lipopolysaccharide (LPS, 0.5 μg / ml) for 24 hours to confirm the expression of pro-inflammatory cytokines TNF-α and IL-6 by THP-1 cells, and the NF-κB signaling pathway associated with their expression.

[0108] When THP-1 cells were treated with LPS, the expression of the pro-inflammatory cytokines TNF-α and IL-6 increased, and their expression was effectively inhibited by treatment with compound 1 (Figure 1a); the expression of such pro-inflammatory cytokines increased via activation of the NF-κb signaling pathway, and the nuclear translocation of p50 and p65 associated with the NF-κb signaling pathway was effectively inhibited by compound 1 (Figure 1b). These results confirm that the expression of pro-inflammatory cytokines by immune cells is effectively inhibited by compound 1, and can be interpreted as demonstrating the potential use of compound 1 in the treatment of inflammatory diseases.

[0109] (Example 3) Evaluation of the regulatory activity of the compounds according to the present invention on regulatory T cell and Th17 cell differentiation. Using naive T cells from mouse spleens, compound 1 was thoroughly dissolved in DMSO to create differentiation conditions for regulatory T cells and Th17 cells, and differentiation was confirmed. Harmine was used as a control in the experiment.

[0110] The results, as shown in Figure 2, showed that when treated with compound 1, regulatory T cells (T) were reduced. regIncreased differentiation of ) and decreased differentiation of Th17 cells were observed, suggesting potential use in the treatment of inflammatory diseases, such as autoimmune diseases.

[0111] (Example 4) Evaluation of the efficacy of the compound of the present invention using a mouse model of collagen-induced arthritis. In this experiment, male DBA-1 mice aged 8 to 10 weeks were used as an animal model. Bovine type II collagen (CII) was mixed with an equal amount of complete Freudian adjuvant, and 100 μL of this mixture was intradermally injected into the tail of DBA-1 mice. After 21 days, the same CII was mixed with an equal amount of incomplete Freudian adjuvant (IFA, Chondrex), and 100 μL of this mixture was then intradermally injected into the tail. Observation of symptoms in the mouse model was started at this point, and arthritis was evaluated every other day. Compound 1 was thoroughly dissolved in a solvent (1% citrate + 20% HP-beta-CD), and then 30 mg / kg was orally administered twice daily for 2 weeks, starting on day 29. In the control group, Enbrel (anti-TNF-α) was administered subcutaneously at a dose of 10 mg / kg every two days, followed by oral administration of dexamethasone (0.15 mg / kg), baricitinib (5 mg / kg), filgotinib (50 mg / kg), and tofacitinib (10 mg / kg) twice daily; for arthritis assessment, scores were obtained by summing the scores from the four paws of the mice based on the mean arthritis index by Rosloniec et al. (Reference 1: Brand DD, et al. Nat Protoc. 2007;2(5):1269-75), and dividing by 4 to obtain the average.

[0112] The scores and criteria for evaluating arthritis are as follows: Score 0: No edema or erythema. Score 1: Mild edema and erythema limited to the foot or ankle. Score 2: Mild edema and erythema from the ankle to the tarsal bones. Score 3: Moderate edema and erythema from the ankle to the metatarsals. Score 4: Severe edema and redness of the skin from the ankle to the entire leg, or stiffness of the leg.

[0113] At the end of the experiment, the weights of the two hind legs of each mouse were measured and added together, and these measurements were compared.

[0114] Furthermore, for histological examination of the joint regions of the control and experimental groups treated with compound 1, the tissues were stained with H&E and T-blue and observed under a light microscope. The degree of articular fibrosis due to necrotic and inflammatory cell infiltration (0 to 5), cartilage structure, cell number and distribution under examination, and synovial inflammation and hyperplasia (Modified Rankin Scores, 0 to 12) were evaluated according to the criteria in Table 3, and the results were compared (Reference 2: Cynthia Shackelford, et al. Toxicologic Pathology. Vol. 30, No. I, p93-96.; Reference 3: Pine PR, et al. Clin Immunol. 124 (3): 244-57). [Table 3-1] [Table 3-2]

[0115] Figure 3 shows the results of evaluating arthritis indicators after inducing inflammation with collagen. The results showed that the arthritis indicators that increased after administration of the compound of the present invention decreased, and the joint weight that increased due to the induction of arthritis decreased (Figures 3a to 3b). Furthermore, based on photographs of the joint region for histological analysis, it was found that treatment with compound 1 reduced the area of ​​cells where collagen-induced inflammation occurred, and also reduced the area of ​​damaged joint (Figures 3c to 3e). From this, it was confirmed that the above compound has the potential to inhibit inflammatory responses and treat and suppress the progression of arthritis.

[0116] (Example 5) Evaluation of inhibitory activity of inflammatory cytokine expression in peripheral blood mononuclear cells (PBMCs) from patients with inflammatory bowel disease. Blood was collected from patients exhibiting inflammatory bowel disease, and peripheral blood mononuclear cells were isolated within 12 hours of collection; the inhibitory activity of compound 1 on inflammatory cytokine secretion in peripheral blood mononuclear cells was investigated by treating them with compound 1 for 24 hours.

[0117] Peripheral blood mononuclear cells in patients with inflammatory bowel disease (IBD) are already activated and express inflammatory cytokines. Treatment of peripheral blood mononuclear cells in patients exhibiting IBD with compound 1 effectively inhibited the expression of the inflammatory cytokines TNF-α, IL-6, and IL-17A. This result can be interpreted as indicating the compound's potential for use in the treatment of IBD (Figure 4).

[0118] (Example 6) Evaluation of the efficacy of compounds using a mouse model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis. In this experiment, male BALB / c mice (8 weeks old) were used. The experimental animals were subjected to a 1-day dietary restriction before treatment with TNBS. Intestinal inflammation was induced by submucosal injection of TNBS (TNBS solution, 1 mg in 0.1 mL of 50% ethanol) into the colon. Control animals that did not show inflammation were administered only a 0.9% NaCl solution without TNBS by submucosal injection into the colon.

[0119] Compound 1 was thoroughly dissolved in a solvent (5% DMSO, 5% PEG400, 90% DDW, 1% Tween® 80) and then administered orally once daily at the prescribed concentration (60 mpk). Cyclosporine A, a comparative compound, was administered orally once daily, and a TNF-α blocker (Enbrel®) was administered intraperitoneally once daily.

[0120] During the experiment, changes in body weight, fecal occult blood, and stool consistency were monitored daily, and serum was collected on day 5 of the experiment. Intestinal tissue was collected at the end of the experiment, and its weight, the degree of polymorphonuclear leukocyte (PMN) deposition, and the degree of myeloperoxidase (MPO) expression were measured.

[0121] As shown in Figure 6, the MPO levels were lower than those of the control group not treated with the compound. Furthermore, the weight of the intestinal tissue decreased in the experimental group treated with compound 1, which can be interpreted as a reduction in edema caused by inflammation. In addition, the inflammatory sites on the collected intestinal tissue were stained with H&E and photographed under a light microscope, and the results showed that the thickness of the lamina propria, which had increased due to the induction of inflammation, was reduced by treatment with the compound of the present invention (Figure 5).

[0122] (Example 7) Evaluation of the efficacy of compounds using a mouse model of DSS-induced inflammatory bowel disease. The animals used in this experiment were male C57BL / 6 mice (6 to 8 weeks old) weighing 20 to 24 g, purchased from Charles River Laboratories. All mice except the normal control were given 3% DSS water for 5 days to induce enteritis.

[0123] Starting the day after inducing enteritis, compound 1 was thoroughly dissolved in a solvent (0.5% citrate in dH2O) and then administered orally twice daily at the prescribed concentration (20 mg / kg). Cyclosporine A, a comparative compound, was dissolved in 0.5% methylcellulose solvent and administered orally once daily at the prescribed concentration (20 mg / kg), while tofacitinib was dissolved in 0.5% methylcellulose solvent and administered orally twice daily at the prescribed concentration (10 mg / kg).

[0124] Body weight changes, fecal occult blood, and stool consistency were monitored daily throughout the experiment to assess the degree of disease activity. At the end of the experiment (day 12), intestinal tissue was collected, its weight and length were measured, and histological analysis was performed using H&E staining and PAS staining to analyze the expression of inflammatory cytokines in the intestinal tissue.

[0125] To assess disease activity, scoring was performed using the changes in weight and other criteria disclosed in Table 4 below; and the scores were compiled. [Table 4]

[0126] The results, as shown in Figure 7, demonstrated that treatment with the compound reduced weight loss compared to the untreated control group, and disease activity decreased to the level of the control group administered cyclosporine A. Furthermore, as shown in Figure 8, the length-to-weight ratio of intestinal tissue increased with increasing severity of colitis, but administration of compound 1 decreased this ratio, and histological analysis confirmed a reduction in goblet cell loss. In addition, administration of compound 1 was confirmed to reduce the expression of inflammatory cytokines (TNR-α, IL-6, IL-17A) that increase as inflammation in the intestinal tissue worsens. In summary, compound 1 was confirmed to reduce symptoms caused by colitis (diarrhea, fecal occult blood, and inflammatory markers), and the results can be interpreted as confirming its potential use in the treatment of colitis.

[0127] (Example 8) Evaluation of the efficacy of compounds using a house dust mite-induced atopic dermatitis model. Eight-week-old NC / Nga mice had their backs and ears shaved, and atopic dermatitis was induced by applying 0.1 g of a mite cream once every three days for a total of seven times. Negative control mice, which did not develop dermatitis, were given a mite-free cream. After inducing atopic dermatitis, compound 1 was thoroughly dissolved in a solvent (0.5% citrate), and then administered orally at formulation concentrations of 10, 20, and 30 mpk twice daily for 14 days. The comparative control group received the JAK1 inhibitor upadacitinib at 6 mg / kg twice daily for 14 days.

[0128] After inducing atopic dermatitis with a house dust mite cream, the symptoms and condition of the skin on the ears and back were scored twice a week from the first day of administration; the measured values ​​were added together, and the average is shown in Figure 9. Furthermore, on the last day of the experiment, skin tissue and serum were collected, and the levels of inflammatory cytokine expression in the tissue and the levels of IgE expression in the serum were observed using ELISA analysis; the results are shown in Figure 10.

[0129] The results showed that dermatitis of the back and ears was alleviated in a concentration-dependent manner with the administration of compound 1, with 30 mpk being the most effective in alleviating dermatitis; compound 1 was confirmed to be more effective in reducing atopic dermatitis than the upadacitinib control group. Worsening of atopic dermatitis leads to an increase in inflammatory cytokines that induce inflammation in the lesional area, and a statistically significant decrease in the expression of inflammatory cytokines in the back tissue of the group administered compound 1 at 30 mpk was observed compared to the control group. Furthermore, it has been reported that serum IgE increases when atopic dermatitis is induced in a house dust mite cream-induced atopic dermatitis model, and a concentration-dependent decrease in IgE expression was observed in the group administered compound 1, with a statistically significant decrease observed in the group administered 30 mpk. From the above results, it can be confirmed that compound 1 has a therapeutic effect on atopic dermatitis.

[0130] (Example 9) Evaluation of in-vivo stability and bioavailability of compounds according to the present invention To evaluate the in-vivo stability and bioavailability of Compound 1 according to the present invention for use as a drug, metabolic stability assessment, metabolic enzyme CYP inhibition assay, hERG analysis, CaCo-2 analysis to observe the permeability of the drug to biological membranes, and plasma stability assessment were performed. The results are shown in Table 5 below. MS is an indicator of in-vivo metabolic stability, and the value confirmed that Compound 1 is safe in large animals ranging from mice to dogs.

[0131] Drug interactions (DDIs) can be observed in CYP inhibition assays. Using a luminescence assay, inhibitory activity against 1A2, 2C9, 2C19, 2D6, and 3A4, key Phase I drug-metabolizing CYP450 enzymes involved in drug metabolism, was measured and evaluated. While CYP3A4 indicators are typically suppressed, the enzyme inhibitory activity of the compounds of the present invention was almost negligible.

[0132] hERG analysis is used as an indicator of cardiotoxicity, and a value of 5 μM generally indicates safety; the compound of the present invention has been confirmed to have excellent safety in terms of cardiotoxicity.

[0133] Caco-2 permeability is used to observe the cell membrane permeability of a drug and can be considered an indicator related to drug absorption and excretion. An ER ratio close to "1" indicates nearly equivalent drug absorption and excretion, and the compound of the present invention showed a value of 1.08, confirming that it has excellent cell membrane permeability.

[0134] Hydrolysis in plasma, along with metabolic reactions, is a factor that influences the rapid in-vivo degradation of drugs and their short half-lives; plasma stability is a test that evaluates these. A specific concentration of a compound was added to plasma, reacted for a specific period of time, then collected, and the percentage of the compound remaining relative to the amount before the reaction was measured using LC-MS / MS.

[0135] Even after two hours, 97.2% of the compound of the present invention remained in the plasma without degradation, thus demonstrating excellent plasma stability. [Table 5]

[0136] (Example 10) Evaluation of the topical anti-inflammatory activity of compound 1 in imiquimod (IMQ)-induced psoriasis-like dermatitis. Compound 1 (0.3%, 1%, and 3%) and the vehicle (5% DMSO / 75% PEG400 / 20% EtOH) were administered topically to the right ear of mice at a dose of 20 μL / mouse once daily (QD) for 9 consecutive days. The reference compound, dexamethasone (0.15%), was applied topically to the right ear of mice at a dose of 20 μL / mouse once daily (QD) during the same study period.

[0137] Imiquimod (IMQ) cream (5%) (Aldara; 3M Pharmaceuticals) 15 mg was administered topically once daily (QD) to the right ear one hour after treatment (converted to a daily dose of 0.75 mg of the active compound) for nine consecutive days from day 1 to day 9.

[0138] Ear swelling was measured on day 0, and then 30 minutes before medication on days 2, 4, 6, and 8. On day 10, ear swelling was measured 24 hours after the last medication dose.

[0139] The results are shown in Figures 11a and 11b. Topical application of 5% IMQ cream, a TLR7 / 8 ligand and potent immunoactivator, to the ears of mice induced psoriasis-like inflammation and showed a significant increase (p<0.05) in ear swelling compared to the sham control, demonstrating successful induction of IMQ-induced psoriasis in the untreated group. However, topical administration of the vehicle control (5% DMSO / 75% PEG400 / 20% EtOH) was associated with a significant (p<0.05) decrease in IMQ-induced ear swelling from day 6 to day 10 compared to the untreated group.

[0140] Compound 1 (0.3%, 1%, and 3%) moderately to significantly (p<0.05) inhibited IMQ-induced ear swelling from day 6 to day 10 in a dose-dependent manner compared to the untreated and vehicle control groups. The reference compound, dexamethasone (0.15%), significantly reduced IMQ-induced ear swelling (p<0.05) in BALB / c mice.

[0141] No significant difference in left ear thickness was observed between the untreated group and the vehicle control group; however, topical administration of dexamethasone (0.15%) also resulted in a significant (p<0.05) reduction in left ear swelling during the study period. Ear weight measurements were consistent with net swelling measurements. Weight gain was similar between the vehicle control group and the treatment group, and only dexamethasone showed a significant (p<0.05) reduction in weight during the study period.

[0142] Histopathological examination of ear skin revealed epidermal hyperplasia, multifocal to diffuse inflammatory cell infiltration, multifocal necrosis, and hyperkeratotic lesions in the untreated and vehicle control groups. The severity of skin lesions was significantly attenuated by dexamethasone (0.15%) and compound 1 (3%) compared to the untreated and vehicle control groups.

[0143] Finally, compound 1 (3%, high dose) was administered topically at 20 μL / mouse, QD × 9 days, demonstrating a significant (p<0.05) protective effect in IMQ-induced psoriasis-like inflammation, as evidenced by improvements in ear swelling, ear weight, and histopathological outcomes in IMQ-induced psoriasis models in BALB / c mice.

[0144] (Example 11) Evaluation of the oral anti-inflammatory activity of compounds in imiquimod (IMQ)-induced psoriasis-like dermatitis. Compound 1 at 45 and 60 mg / kg, along with a vehicle (0.5% citrate + 20% HP-b-CD in DDW) at 5 mL / kg, was administered twice daily (BID) for 9 consecutive days via oral gastrostomy tube. Positive controls, methotrexate at 2 mg / kg and tofacitinib at 5 mg / kg, were administered twice daily (BID) via oral gastrostomy tube during the same study period.

[0145] Imiquimod (IMQ) cream (5%) (Aldara; 3M Pharmaceuticals) 15 mg was administered topically (QD) to the right ear once daily (TOP) one hour after treatment (converted to a daily dose of 0.75 mg of the active compound) for nine consecutive days from day 1 to day 9. Ear swelling was measured on day 0, and then 30 minutes before administration on days 2, 4, 6, and 8. On day 10, ear swelling was measured 24 hours after the last administration.

[0146] The results are shown in Figures 12a and 12b. Topical application of 5% IMQ cream, a TLR7 / 8 ligand and potent immunoactivator, to the ears of mice induced psoriasis-like inflammation and showed a significant increase (p<0.05) in ear swelling compared to sham controls, demonstrating successful induction of IMQ-induced psoriasis in both the untreated and vehicle control (0.5% citrate + 20% HP-b-CD in DDW) groups.

[0147] Compound 1, administered at 45 and 60 mg / kg, statistically significantly inhibited IMQ-induced ear swelling from day 8 to day 10 compared to the vehicle group (p<0.05).

[0148] The positive control, methotrexate at 2 mg / kg, showed a significant (p<0.05) effect on IMQ-induced ear swelling on day 8 compared to the vehicle group. Tofacitinib administered at 5 mg / kg also showed significant (p<0.05) inhibition of IMQ-induced ear swelling from day 8 to day 10 in the study.

[0149] All treatment groups showed a slight but significant difference in left ear thickness compared to the vehicle group throughout the study period. Ear weight measurements were consistent with net swelling measurements.

[0150] Weight gain was similar between the vehicle control group and the treatment group throughout the study period. However, with methotrexate at a dose of 2 mg / kg, BID x 9 days, weight significantly decreased between day 9 and day 10 of the study.

[0151] Finally, compound 1 at 45 and 60 mg / kg PO, BID × 9 days showed a significant protective effect (p<0.05) in IMQ-induced psoriasis-like inflammation, as evidenced by the improvement of ear swelling in IMQ-induced psoriasis models in BALB / c mice.

[0152] While several embodiments of the present invention have been described, it is clear that these basic embodiments may be modified to provide other embodiments utilizing the compounds and methods of the present invention. Therefore, the scope of the present invention should be defined by the appended claims rather than by the specific embodiments presented as examples.

Claims

1. A pharmaceutical composition for preventing and / or treating an inflammatory disease in a patient in need thereof, the pharmaceutical composition comprising a compound represented by formula 1: [C6] or an isomer or a pharma- ceutically acceptable salt thereof, wherein R 1 is C 1 ~C 3 is an alkoxy; R 2 and R 3 are each independently hydrogen, a straight or branched chain C 1 ~C 10 Alkyl, or C 3 ~C 6 is cycloalkyl, R 4 is haloalkyl.

2. The prevention and / or treatment of the inflammatory disease comprises: (a) reducing pro-inflammatory cytokines in said patient; (b) determining whether the patient has a regulatory T cell (T reg ) differentiation; and (c) reducing pro-inflammatory T cells in said patient. The composition of claim 1 comprising one or more of:

3. 1. A pharmaceutical composition for reducing a proinflammatory cytokine in a patient in need thereof, the pharmaceutical composition comprising a compound represented by formula 1: [C7] or an isomer or a pharma- ceutically acceptable salt thereof, wherein R 1 is C 1 ~C 3 is an alkoxy; R 2 and R 3are each independently hydrogen, a straight or branched chain C 1 ~C 10 Alkyl, or C 3 ~C 6 is cycloalkyl, R 4 is haloalkyl.

4. 4. The composition of claim 2 or claim 3, wherein the pro-inflammatory cytokine is selected from one or more of NO, IFN-γ, IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17, IL-17A, IL-22, IL-23, KC, MIP-1a, MIP-1b, GM-CSF, and TNF-α.

5. Regulatory T cells (T reg ) in patients requiring increased differentiation of T reg 1. A pharmaceutical composition for increasing differentiation of a medicament comprising a compound of formula 1: [C8] or an isomer or a pharma- ceutically acceptable salt thereof, wherein R 1 is C 1 ~C 3 is an alkoxy; R 2 and R 3 are each independently hydrogen, a straight or branched chain C 1 ~C 10 Alkyl, or C 3 ~C 6 is cycloalkyl, R 4 is haloalkyl.

6. 1. A pharmaceutical composition for reducing pro-inflammatory T cells in a patient in need thereof, the pharmaceutical composition comprising a compound of formula 1: [C9] or an isomer or a pharma- ceutically acceptable salt thereof, wherein R 1 is C 1 ~C 3 is an alkoxy; R 2 and R 3 are each independently hydrogen, a straight or branched chain C 1 ~C 10 Alkyl, or C 3 ~C 6 is cycloalkyl, R 4 is haloalkyl.

7. The composition of claim 2 or claim 6, wherein the pro-inflammatory T cells are Th17.

8. R 1 The composition of claim 1 , wherein is methoxy.

9. R 2 is a linear or branched chain C 1 ~C 5 9. The composition of claim 1, wherein the alkyl group is an alkyl group.

10. R 2 C 3 ~C 4 9. The composition of claim 1, wherein the aryl group is cycloalkyl.

11. R 3 The composition of claim 1 , wherein is hydrogen.

12. R 4 The composition of any one of claims 1 to 11, wherein is trifluoromethyl.

13. The compound represented by Chemical Formula 1 is (1) (4-((-4-ethylamino)-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino)-3-methoxyphenyl)(4-morpholinopiperidin-1-yl)methanone; (2) (3-methoxy-4-((4-(methylamino)-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino)phenyl)(4-morpholinopiperidin-1-yl)methanone; (3) (4-(4-(isopropylamino)-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-6-ylamino)-3-methoxyphenyl)(4-morpholinopiperidin-1-yl)methanone; (4) (S)-(4-((4-(2-butylamino)-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino)-3-methoxyphenyl)(4-morpholinopiperidin-1-yl)-methanone; or (5) (4-((4-(cyclopropylamino)-3-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)3-methoxyphenyl)(4-morpholinopiperidin-1-yl)methanone.

14. The composition of any one of claims 1 to 13, wherein the compound represented by Chemical Formula 1 is (4-((-4-ethylamino)-3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino)-3-methoxyphenyl)(4-morpholinopiperidin-1-yl)methanone.

15. The inflammatory disease is selected from the group consisting of graft-versus-host disease (GvHD), obstructive airway disease, chronic obstructive pulmonary disease, allergies, systemic lupus erythematosus, scleroderma, inflammatory bowel disease (e.g., ulcerative colitis and Crohn's disease), atopic dermatitis, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular degeneration, uveitis, conjunctivitis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic kidney disease, nephritis, Sjogren's syndrome, autoimmune pancreatitis, periodontal disease, alopecia areata, chronic pelvic peritonitis, endometriosis, rhinitis, tonsillitis, otitis media, pharyngitis, cystitis, chronic prostate adenitis, eye diseases and conditions, e.g. ocular allergies, keratoconjunctivitis sicca, vernal conjunctivitis, diseases affecting the nose, including allergic rhinitis, and inflammatory diseases involving an autoimmune response or having an autoimmune component or etiology, including autoimmune blood disorders (e.g. hemolytic anemia, aplastic anemia, pure red cell aplasia, and idiopathic thrombocytopenia), polychondritis, Wegener's granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Stevens-Johnson syndrome, idiopathic sprue, irritable bowel syndrome, celiac disease, periodontitis, pulmonary hyaline membrane disease, renal disease, glomerular disease, alcoholic Liver disease, multiple sclerosis, endocrine eye disorders, Becker / Duchenne muscular dystrophy, Graves' disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, primary biliary cirrhosis, uveitis (anterior and posterior), interstitial pulmonary fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, cryopyrin-associated periodic syndromes, vasculitis, diverticulitis, interstitial cystitis, glomerulonephritis (with or without nephrotic syndrome including e.g. idiopathic nephrotic syndrome or minimal change nephropathy), chronic granulomatous diseases, leptospirosis, kidney disease, glaucoma, retinal disease, ageing, headaches, Pain, Complex Regional Pain Syndrome, Cardiac Hypertrophy, Muscle Atrophy, Catabolic Disorders, Obesity, Fetal Growth Retardation, Hypercholesterolemia, Cardiac Disease, Chronic Heart Failure, Mesothelioma, Anhidrotic Ectodermal Dysplasia, Behcet's Disease, Incontinentia Pigmenti, Paget's Disease, Pancreatitis, Hereditary Periodic Fever Syndromes, Asthma (Allergic and Non-Allergic, Mild, Moderate, Severe, Bronchitis, and Exercise-Induced), Acute Lung Injury, Acute Respiratory Distress Syndrome, Hypereosinophilia, Hypersensitivity, Rhinosinusitis, Ocular Allergies, Silica-Induced Disease, COPD (Injury, Airway Inflammation, Bronchial Hyperresponsiveness, Remodeling, or Reduction in Disease Progression), Pulmonary Disease,Cystic fibrosis, acid-induced lung injury, pulmonary hypertension, polyneuropathy, cataracts, muscle inflammation with systemic sclerosis, inclusion body myositis, myasthenia gravis, thyroiditis, Addison's disease, lichen planus, diabetes mellitus (type 1 or type 2), appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic graft rejection, colitis, dacryoadenitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, small intestine colitis, epicondylitis, epididymitis, fasciitis, connective tissue inflammation, gastritis, gastroenteritis, Henoch's disease 15. The composition according to any one of claims 1 to 14, wherein the inflammation is selected from Schonlein's purpura, hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis, myocarditis, myocarditis, nephritis, oophoritis, orchitis, osteitis, otitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, ulcerative colitis, vaginitis, vasculitis, and vulvitis.

16. 16. The composition of any one of claims 1 to 15, wherein the inflammatory disease is selected from inflammatory bowel disease, rheumatoid arthritis, lupus, psoriasis, atopic dermatitis, graft versus host disease (GvHD), acute lung injury, alopecia areata, diabetes, and / or osteoarthritis.

17. 17. The composition of any one of claims 1 to 16, wherein the compound represented by Chemical Formula 1 prevents and / or inhibits or otherwise beneficially affects protein kinase activity.

18. A composition according to any one of claims 1 to 17, characterized in that it is administered together with at least one additional active ingredient.

19. At least one additional active ingredient is selected from the group consisting of gamma globulins, phosphodiesterase inhibitors (e.g., apremilast), IRAK4 inhibitors, belimumab, tacrolimus, rapamycin, mycophenolate mofetil, interferons, paracetamol, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDS), such as aspirin, ibuprofen, naproxen, etodolac (Lodine®), celecoxib, and colchicine (Colcrys®), corticosteroids, such as prednisone, prednisolone, , methylprednisolone, hydrocortisone, betamethasone, etc., probenecid, allopurinol, febuxostat (Uloric®), sulfasalazine (Azulfidine®), antimalarials such as hydroxychloroquine (Plaquenil®) and chloroquine (Aralen®), methotrexate (Rheumatrex®), gold salts such as gold thioglucose (Solganal®), gold thiomalate (Myochrysine®), and oncolytic drugs such as cyclosporine (Cyclosporin®), ... -lanofin (Ridaura®), D-penicillamine (Depen® or Cuprimine®), azathioprine (Imuran®), cyclophosphamide (Cytoxan®), chlorambucil (Leukeran®), cyclosporine (Sandimmune®), leflunomide (Arava®), and "anti-TNF" agents such as etanercept (Enbrel®), infliximab (Remicade®), golimumab (Si mponi®), certolizumab pegol (Cimzia®), and adalimumab (Humira®), "anti-IL-1" agents such as anakinra (Kineret®) and rilonacept (Arcalyst®), canakinumab (Ilaris®), anti-JAK / STAT inhibitors such as tofacitinib, baricitinib, and GLPG0634, antibodies such as rituximab (Rituxan®), "anti-T cell" agents such as abatacept (Orencia®),"Anti-IL-6" agents such as tocilizumab (Actemra®), diclofenac, cortisone, hyaluronic acid (Synvisc® or Hyalgan®), monoclonal antibodies such as tanezumab, anticoagulants such as heparin (Calcinparine® or Liquaemin®), and warfarin (Coumadin®), antidiarrheal drugs such as diphenoxylate (Lomotil®) and loperamide (Imodium®), bile acid binders combination drugs such as cholestyramine, alosetron (Lotronex®), lubiprostone (Amitiza®), laxatives such as milk of magnesia, polyethylene glycol (MiraLax®), Dulcolax®, Correctol®, and Senokot®, anticholinergics or antispasmodics such as dicyclomine (Bentyl®), Singulair®, beta-2 agonists such as albuterol (Ventolin® HFA, anticholinergics, such as ipratropium bromide (Atrovent®) and tiotropium (Spiriva®), inhaled corticosteroids, such as levalbuterol (Xopenex®), metaproterenol (Alupent®), pirbuterol acetate (Maxair®), terbutaline sulfate (Brethair®), salmeterol xinafoate (Serevent®), and formoterol (Foradil®), amides such as beclomethasone dipropionate (Beclovent®, Qvar®, and Vanceril®), triamcinolone acetonide (Azmacort®), mometasone (Asthmanex®), budesonide (Pulmocort®), and flunisolide (Aerobid®), Afviar®, Symbicort®, Dulera®, cromolyn sodium (Intal®), methylxanthines such asTheophylline (Theo-Dur®, Theolair®, Slo-Bid®, Uniphyl®, Theo-24®) and aminophylline, IgE antibodies such as omalizumab (Xolair®), nucleoside reverse transcriptase inhibitors such as zidovudine (Retrovir®), abacavir (Ziagen®), abacavir / lamivudine (Epzicom®), abacavir / lamivudine / zidovudine (Trizivir®), didanoside nucleoside reverse transcriptase inhibitors, such as delavirdine (Rescriptor®), efavirenz (Sustiva®), nevirapine (Viramune®), and etravirine (Intelence®); nucleotide reverse transcriptase inhibitors, such as tenofovir (Viread®), protease inhibitors, such as amprenavir (Agenerase®), atazanavir (Reyataz®), darunavir (Prezista®), fosamprenavir (Lexiva®), indinavir (Crixivan®), lopinavir and ritonavir (Kaletra®), nelfinavir (Viracept®), ritonavir (Norvir®), saquinavir (Fortovase®, or Invirase®), and tipranavir (Aptivus®), entry inhibitors such as enfuvirtide (Fuzeon®) and maraviroc (Selzentry®), integrase inhibitors such as raltegravir (Isentress®), doxorubicin (Hydrodaunorubicin®), vincristine (Oncovin®), optionally in combination with lenalidomide (Revlimid®),19. The composition of claim 18, selected from bortezomib (Velcade®), and dexamethasone (Decadron®), or any combination thereof.

20. 20. The pharmaceutical composition of claim 1, further comprising an excipient, a disintegrant, a sweetener, a lubricant, and / or a flavoring agent.